Pemivibart, sold under the brand name Pemgarda, is a monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID‑19.
[3][5] The US Food and Drug Administration (FDA) issued an emergency use authorization for pemivibart in March 2024.
[4] It is authorized for individuals who are not currently infected with SARS‑CoV‑2 and who have not had a known recent exposure to an individual infected with SARS‑CoV‑2; and who have moderate-to-severe immune compromise due to a medical condition or due to taking immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID‑19 vaccination.
[2][3][6][7] The US Food and Drug Administration (FDA) issued an emergency use authorization for pemivibart in March 2024.
[9] This article incorporates public domain material from the United States Department of Health and Human Services